These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23651036)

  • 1. Preventive effects of Monascus on androgen-related diseases: androgenetic alopecia, benign prostatic hyperplasia, and prostate cancer.
    Chiu HW; Chen MH; Fang WH; Hung CM; Chen YL; Wu MD; Yuan GF; Wu MJ; Wang YJ
    J Agric Food Chem; 2013 May; 61(18):4379-86. PubMed ID: 23651036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer.
    Kucerova R; Bienova M; Kral M; Bouchal J; Trtkova KS; Burdova A; Student V; Kolar Z
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):91-6. PubMed ID: 24665929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quisqualis indica Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis.
    Ub Wijerathne C; Park HS; Jeong HY; Song JW; Moon OS; Seo YW; Won YS; Son HY; Lim JH; Yeon SH; Kwun HJ
    Biol Pharm Bull; 2017 Dec; 40(12):2125-2133. PubMed ID: 28943529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of Ponciri Fructus on testosterone-induced benign prostatic hyperplasia in rats.
    Jeon WY; Kim OS; Seo CS; Jin SE; Kim JA; Shin HK; Kim YU; Lee MY
    BMC Complement Altern Med; 2017 Aug; 17(1):384. PubMed ID: 28774334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia.
    Shin IS; Lee MY; Jung DY; Seo CS; Ha HK; Shin HK
    Food Chem Toxicol; 2012 Mar; 50(3-4):884-8. PubMed ID: 22266360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats.
    Wu JH; Jiang XR; Liu GM; Liu XY; He GL; Sun ZY
    Toxicol Ind Health; 2011 Oct; 27(9):810-9. PubMed ID: 21415097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia.
    Park BK; Kim CW; Kwon JE; Negi M; Koo YT; Lee SH; Baek DH; Noh YH; Kang SC
    Pharm Biol; 2019 Dec; 57(1):90-98. PubMed ID: 30724641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of Tripterygium wilfordii multiglycoside on benign prostatic hyperplasia in rats.
    Shen HN; Xu Y; Jiang ZZ; Huang X; Zhang LY; Wang T
    Chin J Nat Med; 2015 Jun; 13(6):421-7. PubMed ID: 26073338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
    Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
    Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of zinc on N-methyl-N-nitrosourea and testosterone-induced prostatic intraepithelial neoplasia in the dorsolateral prostate of Sprague Dawley rats.
    Banudevi S; Elumalai P; Sharmila G; Arunkumar R; Senthilkumar K; Arunakaran J
    Exp Biol Med (Maywood); 2011 Sep; 236(9):1012-21. PubMed ID: 21865407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum androgens and prostate-specific antigen levels in androgenetic alopecia: is there a difference between frontal and vertex baldness?
    Lis-Święty A; Arasiewicz H; Ranosz-Janicka I; Brzezińska-Wcisło L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1815-1818. PubMed ID: 29237093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
    BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptolide reduces prostate size and androgen level on testosterone-induced benign prostatic hyperplasia in Sprague Dawley rats.
    Wang YR; Xu Y; Jiang ZZ; Zhang LY; Wang T
    Chin J Nat Med; 2017 May; 15(5):341-346. PubMed ID: 28558869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
    BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status.
    Torres JM; Ruiz E; Ortega E
    Prostate; 2003 Jun; 56(1):74-9. PubMed ID: 12746849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia.
    Nejishima H; Yamamoto N; Suzuki M; Furuya K; Nagata N; Yamada S
    Prostate; 2012 Oct; 72(14):1580-7. PubMed ID: 22430536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
    Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
    Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PPAR-α agonist fenofibrate in the treatment of induced benign prostatic hyperplasia with dysplastic changes in rats.
    Refaie MMM; Rifaai RA; Zenhom NM
    Fundam Clin Pharmacol; 2018 Dec; 32(6):617-626. PubMed ID: 29862557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.